Letter

“Polypill” to fight cardiovascular disease: Interpretation of trial data is optimistic

BMJ 2003; 327 doi: 10.1136/bmj.327.7418.808-b (Published 2 October 2003)
Cite this as: BMJ 2003;327:808.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Gerd Assmann (assmann@uni-muenster.de), professor of laboratory medicine,
  2. Paul Cullen, research physician,
  3. Helmut Schulte, statistician
  1. Institute of Arteriosclerosis Research, University of Münster, Domagkstrasse 3, D-48149 Münster, Germany

    EDITOR—Rarely has the demand for empirical evidence of treatment benefit been as necessary as in the prevention of cardiovascular disease. Wald and Law doubt this approach, saying that a “Polypill” containing six drugs would reduce events of ischaemic heart disease by 88% and stroke by 80% and might therefore be given with impunity to …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular